Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NU100 in relapsing forms of multiple sclerosis
2011-002683-24Phase 3Active
- Sponsor
- Nuron Biotech, Inc.
- Start
- Nov 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of interferon beta-1b in multiple sclerosis (MS) (3 arms), sponsored by Nuron Biotech, Inc. Primary endpoint: New contrast-enhancing lesions (CALs) after 4 months of treatment in Cohort 1. Started Nov 2011; status: active.
02
Drugs
interferon beta-1b
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2011-002683-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002683-24.